When Is Dual Immunotherapy Most Appropriate in the Management of Metastatic Non-small Cell Lung Cancer?
Global Advances in Oncology and Hematology · 2026-09 · 1 (1) · 112-117
DOI: 10.4103/gaoh.gaoh_7_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Advances in Oncology and Hematology, online erschienen am 05.09.2026. Verfasst von Nabih Naim und 4 weiteren Autor:innen. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Dual immune checkpoint blockade has expanded first-line treatment options for metastatic non-small cell lung cancer (NSCLC) without sensitizing epidermal growth factor receptor/anaplastic lymphoma kinase alterations, offering durable disease control and long-term survival in selected patients. Three phase III programs define current approaches: CheckMate 227, CheckMate 9LA, and POSEIDON.
Objectives
The objective of this study was to compare dual-immunotherapy strategies across key practice-defining phenotypes [programmed death-ligand 1 (PD-L1)–negative disease, baseline brain metastases, squamous histology, and clinical frailty] and to identify where each regimen appears most compelling based on durability, early disease control, intracranial activity, and tolerability. Materials and Methods: A qualitative synthesis of pivotal trial data was performed, focusing on subgroup-specific outcomes relevant to real-world clinical decision-making. Evidence Synthesis: In PD-L1–negative disease, CheckMate 9LA offers the strongest combined evidence for early disease control and long-term survival. Chemo-free nivolumab/ipilimumab demonstrates the most robust and mature data for intracranial activity and durable benefit, particularly relevant for patients with baseline brain metastases or limited chemotherapy tolerance. In squamous histology, CheckMate 9LA provides the clearest long-term survival signal. Evidence in frail or comorbidity-burdened populations remains limited, though supportive data suggest feasibility of chemo-free dual immunotherapy in selected patients.
Conclusion
Optimal use of dual immunotherapy in metastatic NSCLC should be phenotype-driven rather than uniform. Distinct dual-checkpoint strategies offer complementary strengths across clinically relevant subgroups, supporting individualized treatment selection in routine practice.
Zitieren
APA
Naim, N., Haddad, F., Harmouche, C., Dabar, G., & Kourie, H. R. (2026). When Is Dual Immunotherapy Most Appropriate in the Management of Metastatic Non-small Cell Lung Cancer?. Global Advances in Oncology and Hematology, 1(1), 112-117. https://doi.org/10.4103/gaoh.gaoh_7_26
Vancouver
Naim N, Haddad F, Harmouche C, Dabar G, Kourie HR. When Is Dual Immunotherapy Most Appropriate in the Management of Metastatic Non-small Cell Lung Cancer?. Global Advances in Oncology and Hematology. 2026;1(1):112-117. doi:10.4103/gaoh.gaoh_7_26
BibTeX
@article{Naim2026,
author = {Naim, Nabih and Haddad, François and Harmouche, Carine and Dabar, Georges and Kourie, Hampig Raphael},
title = {When Is Dual Immunotherapy Most Appropriate in the Management of Metastatic Non-small Cell Lung Cancer?},
journal = {Global Advances in Oncology and Hematology},
year = {2026},
volume = {1},
number = {1},
pages = {112--117},
doi = {10.4103/gaoh.gaoh_7_26}
}
EUVIMED